[Video] Implementing a Managed Entry Agreement within the EU: Key Points for Acceptance and Success
By NextLevel Life Sciences - February 19, 2016

Leading up to NextLevel Pharma’s PharmAccess Leaders Forum Spring 2016, we would like to share with you a presentation from the 2015 event to give you an insight into the topics the 2016 event will build upon:

Philip Spearpoint, Principal Consultant at Pope Woodhead on:
“Implementing a Managed Entry Agreement within the EU Key Points for Acceptance and Success”

Register now & join market access leaders in London at the PharmAccess Leaders Forum Spring 2016!Our Managed Entry Agreement workshop will focus on clarification of the terminology and types of approaches, key drivers and success factors for MEAs with relevant case studies, forward-looking trends in the use and impact of MEAs, and cross-learning between the EU and USA. It will also examine principles and practical steps to define an MEA strategy and select the right MEA concept for the product.


PHILIP SPEARPOINT, Principal Consultant, Pope Woodhead, UK:

Philip has worked as a consultant for 8 years, prior to joining PW he spent time at Thompson Reuters and Quintiles initially working in clinical trial development and subsequently in pricing and reimbursement and market access.

His experience spans commercial and clinical trial strategy.

He has led a range of projects to assess P&R potential including aspects of innovative pricing and launch sequencing which have included research with KOLS and payers.

Philip has a PhD in Virology and Drug Development from UCL and BSc in Microbiology from the University of Manchester.

For more information regarding NextLevel Pharma’s Managed Entry Agreement Workshop click here.